Hepatitis C Virus (HCV) and its Genetic Diversity in clinical Isolates from Uttarakhand Population

  • Monika Kuriyal
  • Anjali Bhandari
  • Aaryansh Kumar Suman
  • Dheeraj Shootha
  • Yati Gairola
  • Narotam Sharma
  • Satish Chandra Nautiyal

Abstract

Hepatitis C is major cause of chronic liver disease. It has been recognised as a global health problem because of the progression to cirrhosis and hepatocellular cancer. Quantization and genotyping of HCV RNAs are important to determine the optimal duration of anti-viral therapy and predict likelihood of response. Total 77 samples were tested biochemically, serologically and molecular assay (Roche COBAS TaqMan 48 Real Time PCR). Out of 77 cases 33(42.85%) were with high viral load (>103IU/ ml of HCV RNA) and low viral load (below 103IU/ml) 2 (2.59%) and 42 (54.54%) were target not detected (below 25 IU/ml). Genotype 3 was prevailed with 68.42% out of 35 cases followed by HCV genotype 15.78% in 1, 5.26% in 2 and 6, 2.63% in 1b and 4. In addition, our studies showed that genotype 1, 2, 4 and 6 (mixed genotype was detected in 1 cases with viral load 6.62 × 108IU/ml). Total protein content in serum in all the cases was average except 04 cases that was having low protein content. 02 cases were having low uric acid content that was having high viral load. From all high positive (high viral load) cases which were further diagnosed for their genotyping in which genotype 3 was prevalent following by genotype1, 1b, 2, 4 and  6. Study signifies the gene based diagnosis and its clinical relevance for the proper management of the patients.


Keywords: Hepatitis, Chronic, Real Time PCR, Hepatocellular Carcinoma, Serology

Downloads

Download data is not yet available.

References

1. Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. The Lancet, 2011; 378(9791):571-583.
2. Shukla, D. D., Hoyne, P. A., & Ward, C. W. Evaluation of complete genome sequences and sequences of individual gene products for the classification of hepatitis C viruses. Archives of virology, 1995; 140(10):1747-1761.
3. Leenders, W. P. J. Identification and characterization of the putative hepatocellular receptor for the hepatitis B virus. [Sl: sn]. 1993.
4. Johnston, S. L., & Papadopoulos, N. (Eds.). Respiratory Infections in allergy and Asthma. CRC Press. 2003.
5. Beltrami, E. M., Williams, I. T., Shapiro, C. N., & Chamberland, M. E. Risk and management of blood-borne infections in health care workers. Clinical microbiology reviews, 2000; 13(3):385-407.
6. Aoyagi, K., Ohue, C., Iida, K., Kimura, T., Tanaka, E., Kiyosawa, K., & Yagi, S. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. Journal of clinical microbiology, 1999; 37(6):1802-1808.
7. Lavillette, D., Morice, Y., Germanidis, G., Donot, P., Soulier, A., Pagkalos, E., & Cosset, F. L.. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. Journal of virology, 2005; 79(10):6023-6034.
8. Bartosch, B., Verney, G., Dreux, M., Donot, P., Morice, Y., Penin, F., & Cosset, F. L. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. Journal of virology, 2005; 79(13):8217-8229.
9. Bartosch, B., Verney, G., Dreux, M., Donot, P., Morice, Y., Penin, F., & Cosset, F. L. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. Journal of virology, 2005; 79(13):8217-8229.
10. Balayan, M. S. Epidemiology of hepatitis E virus infection. Journal of viral hepatitis, 1997; 4(3):155-166.
11. Liang, T. J., Rehermann, B., Seeff, L. B., & Hoofnagle, J. H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of internal medicine, 2000; 132(4):296-305.
12. Zahn, A., &Allain, J. P. Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. Journal of General Virology, 2005; 86(3):677-685.
13. World Health Organization. Guidelines for HIV diagnosis and monitoring of antiretroviral therapy (No. SEA-HLM-385rev1). WHO Regional Office for South-East Asia. 2005.
14. World Health Organization. Guidelines for HIV diagnosis and monitoring of antiretroviral therapy, Rev. 2 (No. SEA-HLM-382 (Rev. 2)). WHO Regional Office for South-East Asia. 2009.
15. SOFOSBUVIR, R., AS, P., & CENTER, M. T. XXIII Annual Meeting of the Latin American Association for the Study of the Liver and the National Congress of the Mexican Association of Hepatology. Age, 23, 28y.
16. Adamkiewicz, T. V., Sarnaik, S., & Buchanan, G. R. Pathogenesis and immune. Vaccine, 2003; 21:2093-2096.
17. Trial, V. 647 Lessons from Failure Preparing for Future HIV-1 Vaccine Efficacy Trials.
18. Sharma, N. Cellular and Molecular Profiling of Hepatitis C Virus (HCV) and to Study its Genotypic Heterogeneity in Clinical Isolates. Int J Biotech &Bioeng, 2018; 4(6):119-123.
19. Achord, J. L. (2002). Understanding hepatitis. Univ. Press of Mississippi.
20. Poynard, T., & Imbert-Bismut, F. Laboratory testing for liver disease. Zakim and Boyer’s Hepatology. Elsevier Saunders, 2012; 201-15.
21. Sharma, N. Cellular and Molecular Profiling of Hepatitis C Virus (HCV) and to Study its Genotypic Heterogeneity in Clinical Isolates. Int J Biotech &Bioeng, 2018; 4(6):119-123.
Statistics
51 Views | 76 Downloads
How to Cite
Kuriyal, M., Bhandari, A., Suman, A. K., Shootha, D., Gairola, Y., Sharma, N., & Nautiyal, S. C. (2019). Hepatitis C Virus (HCV) and its Genetic Diversity in clinical Isolates from Uttarakhand Population. Journal of Drug Delivery and Therapeutics, 9(3-s), 280-284. https://doi.org/10.22270/jddt.v9i3-s.2839